Avanir Pharmaceuticals, Inc. (AVNR) Posts Better-Than-Expected Q1 Results
Tweet
Share
E-mailGet Alerts AVNR Hot Sheet
Price: $16.96 --0%
Financial Fact:
Total operating expenses: 40.52M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Total operating expenses: 40.52M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) reported Q1 EPS of ($0.12), $0.01 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $7.2 million versus the consensus estimate of $6.49 million.
For earnings history and earnings-related data on Avanir Pharmaceuticals, Inc. (AVNR) click here.
For earnings history and earnings-related data on Avanir Pharmaceuticals, Inc. (AVNR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Is the global equity rally broadening? UBS weighs in
- Mizuho Reiterates Outperform Rating on Broadcom Limited (AVGO) Into EPS
- S&P 500 may pull back before midterms, but Citi says buy the dip
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
